BioAtla (BCAB) Stock Price, News & Analysis

Company Overview

BioAtla, Inc. (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials. Lead programs include BA3011, a conditionally active antibody targeting cMet for solid tumors, and BA3071, a conditionally active T-cell–engaging bispecific targeting prostate‐specific membrane antigen (PSMA) in metastatic castration-resistant prostate cancer. The company’s research pipeline also features several discovery‐stage CAB molecules directed against tumor-associated antigens and immune checkpoints, reflecting its strategy to address high‐unmet‐need indications.

BioAtla serves a global patient population through internal research and development operations in the United States and China. The company’s R&D infrastructure integrates molecular engineering, translational biology and preclinical pharmacology, enabling rapid optimization of CAB candidates. In addition to its internal programs, BioAtla has entered into strategic collaborations and licensing agreements to accelerate development and broaden the therapeutic reach of its platform.

Led by President and Chief Executive Officer Christian S. Neal, BioAtla’s management team brings extensive experience in antibody engineering, clinical development and regulatory affairs. The company’s mission is to transform the safety and efficacy profile of biologic therapies by harnessing the precision of conditionally active molecules. As BioAtla advances its clinical portfolio, it aims to deliver innovative treatment options that improve patient outcomes and set new standards in targeted oncology therapy.

Key Stats

• Today's Range: $3.27 to $3.54
• 50-Day Range: $3.22 to $4.58
• 52-Week Range: $3.12 to $71.50
• Volume: 39,587 shs
• Average Volume: 33,458 shs
• Market Capitalization: $5.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $200.00
• Consensus Rating: Hold

BioAtla Stock Analysis - MarketRank™

BioAtla scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

BioAtla has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

BioAtla has a consensus price target of $200.00, representing about 5,906.0% upside from its current price of $3.33.

Amount of Analyst Coverage

BioAtla has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioAtla is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioAtla is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.25% of the float of BioAtla has been sold short.

Short Interest Ratio / Days to Cover

BioAtla has a short interest ratio ("days to cover") of 1.92, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioAtla has recently decreased by 18.38%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioAtla does not currently pay a dividend.

Dividend Growth

BioAtla does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for BioAtla this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for BCAB on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioAtla insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.34% of the stock of BioAtla is held by insiders.

Percentage Held by Institutions

77.23% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 8/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BCAB
• CIK: 1826892
• Web: www.bioatla.com
• Phone: 858-558-0708
• Fax: N/A
• Employees: 60
• Year Founded: 2007

Price Target and Rating

• Average Price Target for BioAtla: $200.00
• High Price Target: $200.00
• Low Price Target: $200.00
• Potential Upside/Downside: +5,906.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($41.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$59.61 million
• Net Margins: N/A
• Pretax Margin: -2,530.85%
• Return on Equity: N/A
• Return on Assets: -325.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.15
• Quick Ratio: 0.15

Sales & Book Value

• Annual Sales: $2 million
• Price / Sales: 2.76
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($28.51) per share
• Price / Book: -0.12

Miscellaneous

• Outstanding Shares: 1,660,000
• Free Float: 1,502,000
• Market Cap: $5.53 million
• Optionable: Optionable
• Beta: 0.78